This week, the American College of Rheumatology and the National Psoriasis Foundation released a new treatment guideline for psoriatic arthritis (PsA) that contains evidence-based recommendations on caring for patients with this inflammatory disease.
This week, the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF) released a new treatment guideline for psoriatic arthritis (PsA) that contains evidence-based recommendations on caring for patients with this inflammatory disease.
The guideline was developed using Grading of Recommendations Assessment, Development and Evaluation methodology, and recommendations—many of which are conditional as they were based on low- to very low-quality evidence—were voted on by a panel of rheumatologists, dermatologists, health professionals, and patients.
Among key recommendations of the guideline is a conditional recommendation to use a treat-to-target approach for all patients with active PsA. “Treat-to-target is key, because it encompasses all clinical scenarios, rather than one particular clinical situation,” Jasvinder Singh, MD, MPH, a rheumatologist at the University of Alabama at Birmingham, said in a statement. “The available evidence suggests the irreversible joint damage, associated functional limitations, joint deformities and disability associated with PsA could possibly be avoided/delayed with optimal disease management using a targeted approach. A targeted approach can also improve pain, function and quality of life and social participation.”
Notably, the new guideline also includes a conditional recommendation to use anti—tumor necrosis factor (anti-TNF) therapies as first-line treatment. “The available evidence suggested that in the absence of certain conditions, many treatment-naïve patients would benefit from trying [an anti-TNF] biologic first,” said Dafna Gladman, MD, a rheumatology professor of medicine at the University of Toronto and NPF Medical Board member who served as a content expert during the guideline’s development. “This doesn’t hold true once other symptoms and comorbidities are present,” she added, so oral small-molecule drugs can continue to be an option for patients for whom a biologic is inappropriate.
The guideline also includes a strong recommendation for smoking cessation, particularly based on evidence that smoking reduces biologics’ efficacy (in addition to the fact that smoking is well understood to increase mortality, cancer, and heart and lung diseases).
Finally, the guideline makes a strong recommendation for using anti-TNF monoclonal antibodies instead of etanercept, an anti-TNF soluble receptor biologic, in patients who have concomitant inflammatory bowel disease (IBD). This recommendation, made on the basis of moderate-quality evidence that etanercept is less effective than other options in IBD, is accompanied by strong recommendations for patients with concomitant IBD to use an anti-TNF over an interleukin (IL)-17 inhibitor, and to use an IL-12/IL-23 inhibitor rather than an IL-17 inhibitor.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.